Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. - Wikidata - awgldk - TriplyDB

Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies.

Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies.

http://www.wikidata.org/entity/Q50541835

about

Hemodialysis in Asia Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases Regulatory considerations in oncologic biosimilar drug development Biosimilar: what it is not Biosimilar Insulins: Basic Considerations Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.A comparison of active adverse event surveillance systems worldwide.The approval process for biosimilar erythropoiesis-stimulating agents Update on the safety and bioequivalence of biosimilars - focus on enoxaparin.Biosimilars: Implications for health-system pharmacists.Formulary Selection Criteria for Biosimilars: Considerations for US Health-System Pharmacists Regulatory and clinical considerations for biosimilar oncology drugs Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments.Biosimilar insulins.Clinical safety of biosimilar recombinant human erythropoietins.Improved analytical methods for the detection and quantification of neutralizing antibodies to biopharmaceuticals.Epoetin biosimilars in Europe: five years on.Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.Pharmacovigilance and biosimilars: considerations, needs and challenges.Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease.The ESA scenario gets complex: from biosimilar epoetins to activin traps.Pharmacovigilance in practice: erythropoiesis-stimulating agents.Biosimilar ESAs: a comparative review.State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists.Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.Emerging drugs for the treatment of kidney disease-induced anemia.Autoantibodies to erythropoietin receptor in patients with immune-mediated diseases: relationship to anaemia with erythroid hypoplasia.Safety considerations of biosimilars Efficacy and safety of subcutaneous administration of lyophilized powder of alfa-erythropoietin to maintain hemoglobin concentrations among hemodialysis patients.How bio-questionable are the different recombinant human erythropoietin copy products in Thailand?Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?

P2860

Q26740463-1E71CF5C-58A3-4F35-AAB6-8D1CFB44FFD0 Q27013577-D87F2AB6-9D95-4FB8-AFCE-712AA1043599 Q27027947-D008758D-3F03-43C3-B243-FD5986C9FE9B Q28080880-7E410C02-FC72-4445-B8B1-E21E6A1A2846 Q28646059-FEDDE841-F9E1-48F5-97FE-23AEEDCE686F Q30902172-1698C2E4-6C80-4F13-A84C-1266519BD06E Q34051880-821933F2-D498-4322-8B5F-F6AB80CC3CB6 Q34124734-1B374632-EE2F-4301-A728-E8707CED358D Q34352446-504ADB80-DAE2-4F27-9A47-96CF34005217 Q34372394-8BAE388A-8E57-4630-897C-2ADF385C3554 Q34612781-68040558-2628-400D-A354-6E3C87466D00 Q35505833-1EB369ED-A6C8-4EE5-A896-0D17697E3276 Q37999380-B71BDCF6-EB93-4F38-BFEE-877DECD284D2 Q38009872-FF5305BF-59AB-4FBF-A289-E2A5FB203852 Q38033576-284C1FC2-EE23-432A-A4D2-19FEB24C17F6 Q38046653-FBBB988E-116C-4070-B7CB-E7EEF999CFA4 Q38067654-EE2D0B12-E2C9-48EB-A3BB-45FF5040477F Q38075798-E9E05050-1CE3-483B-B6E2-C081468E5DD7 Q38092850-FE8A7F06-528C-486E-A236-5DE9011D27A4 Q38134288-31BC179D-9A99-485B-92EF-A596DE9AC4F4 Q38205752-1D5E3623-0974-43A0-AC5C-C92EFF9BEE0C Q38217083-0CBA31DC-ACEF-4DE4-8A86-201A98F6F767 Q38263040-D3AB0DEF-C8E2-4C22-B528-C64846CA873D Q38556990-C8F11EF2-BFE1-4256-81BD-79C55F45C39C Q38708927-D235E12C-7B22-4DF5-B4D9-81722A5EC5A3 Q38930912-CEF63AA6-9C99-4450-A12A-0A7DD9A2975D Q39245022-5F37C719-A0C6-479A-B18C-FBB5BDC4DD67 Q42353230-172548C9-8CF4-4FF5-9939-F207702F17BC Q42364444-C1370D31-9D2D-417F-BCDD-0DD0D8E92BC6 Q46120837-5D77235E-7683-4383-B0E3-ED599DAE2E4F Q50107702-32FE67E8-D7FE-43E2-899D-E735153B78DC Q54959955-C61BF5E6-CC45-4B0C-8518-0FB56127641E

P2860

Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies.

http://www.wikidata.org/entity/Q50541835

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Biosimilar recombinant human e ...... on of neutralizing antibodies.

@en

Biosimilar recombinant human e ...... on of neutralizing antibodies.

@nl

type

label

Biosimilar recombinant human e ...... on of neutralizing antibodies.

@en

Biosimilar recombinant human e ...... on of neutralizing antibodies.

@nl

prefLabel

Biosimilar recombinant human e ...... on of neutralizing antibodies.

@en

Biosimilar recombinant human e ...... on of neutralizing antibodies.

@nl

P1433

Q50541835-E778CEF7-C529-4E71-9D8F-9F03D07D6964

P1476

Q50541835-64E8235B-E0D5-4C85-B496-DA988A909831

P2093

Q50541835-19D220B8-9A78-465B-AF2E-F38F5F259D91

Q50541835-4842C5F3-A896-41A2-AD74-CCEA002E6001

Q50541835-52028D3E-B9DF-4EE5-BD61-FF66F8D094C1

Q50541835-755C8661-D688-4F32-892B-2C0F7BDFDD35

Q50541835-7FBDADEE-5CA8-4028-8DE1-5BE2F8FFBAA2

Q50541835-81C72CAB-B36F-4E4D-98A7-C222AE349B34

Q50541835-8204C4D3-2815-45D3-9C6D-734BE8436B69

Q50541835-87B85A8C-F464-4689-A0F5-5DE29A69AE4E

Q50541835-A31370A8-5003-4896-9EEF-A948876BC23C

Q50541835-BBA3ABDC-8220-436E-9581-5163B16B7591

P2888

Q50541835-9EFAD7E8-9D4C-4071-A72B-3B40B54E6375

P304

Q50541835-FD465933-6803-46B4-9789-FA7CC7620E94

P31

Q50541835-AA2206C6-3D5B-4DE5-952F-BEAB0B816330

P356

Q50541835-2A77099C-4CFD-407B-A440-5165A7D03D8B

P407

Q50541835-312E4E96-121F-43BD-825E-CD364F25796B

P433

Q50541835-8E6017A5-D960-4056-AB9C-0B7DB4B34511

P478

Q50541835-BAC3CF5B-29FE-4338-ACC8-7181AA8CC11F

P50

Q50541835-1B1F3D71-798B-4B81-B9E8-49A9593220BB

P577

Q50541835-F094FFB1-8B94-4358-8B1F-A4E9D2E35668

P5875

Q50541835-AEC50FC4-ED01-4CBB-BC50-AD5B353869E9

P698

Q50541835-CC6E98C1-10F9-401A-838B-0BD0C13CF155

P921

Q50541835-237047BB-5E27-42CF-A980-37AE1C060F22

Q50541835-9990724A-BD33-410E-A108-0CFA6229CF1F

P356

P1433

Kidney International

P1476

Biosimilar recombinant human e ...... ion of neutralizing antibodies

@en

P2093

Dusit Lumlertkul

http://www.w3.org/2001/XMLSchema#string

Kearkiat Praditpornsilpa

http://www.w3.org/2001/XMLSchema#string

Khajohn Tiranathanagul

http://www.w3.org/2001/XMLSchema#string

Kriang Tungsanga

http://www.w3.org/2001/XMLSchema#string

Natavudh Townamchai

http://www.w3.org/2001/XMLSchema#string

Paweena Susantitaphong

http://www.w3.org/2001/XMLSchema#string

Pawinee Kupatawintu

http://www.w3.org/2001/XMLSchema#string

Pisut Katavetin

http://www.w3.org/2001/XMLSchema#string

Saengsuree Jootar

http://www.w3.org/2001/XMLSchema#string

Somchai Eiam-Ong

http://www.w3.org/2001/XMLSchema#string

P2888

P304

88-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/KI.2011.68

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

80

http://www.w3.org/2001/XMLSchema#string

P50

Talerngsak Kanjanabuch

P577

2011-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50832016

http://www.w3.org/2001/XMLSchema#string

P698

21430643

http://www.w3.org/2001/XMLSchema#string

P921